Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05597462 · ClinicalTrials.gov registry record · Phase 1
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
A Phase 1 study of Rosacea, sponsored by Journey Medical Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT05597462: Completed Phase 1 study of Rosacea, sponsored by Journey Medical Corporation.
NCT05597462 is a Phase 1 study of Rosacea that has completed, run by Journey Medical Corporation. The registered enrollment target is 60 participants, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05597462, a Phase 1 study of Rosacea, has completed, sponsored by Journey Medical Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this trial is to evaluate the effects of 16-week treatment with DFD-29 40 mg QD dose in comparison to Placebo on the skin, intestinal and vaginal microbiota.
Primary Outcome
Change in the colony forming units (CFUs) of microbial species colonized from skin, gastrointestinal or vaginal swabs from Baseline (BL) to Week 16 in comparison of DFD-29 versus Placebo treatment groups
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Minocycline hydrochloride capsules
Study Locations (2)
New Mexico
- 3A Research, LLC - Las Cruces
Texas
- 3A Research, LLC - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 1 |
What the finished NCT05597462 record still lists
NCT05597462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05597462 reports a single indexed study location in New Mexico, Texas.
Frequently Asked Questions
What is clinical trial NCT05597462 about?
NCT05597462 is a clinical study titled "Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks". The purpose of this trial is to evaluate the effects of 16-week treatment with DFD-29 40 mg QD dose in comparison to Placebo on the skin, intestinal and vaginal microbiota.
What is the current status of trial NCT05597462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-09-30. Estimated completion is 2023-05-30.
What conditions does trial NCT05597462 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT05597462?
The interventions under investigation include: Placebo (OTHER), Minocycline hydrochloride capsules (DRUG).
Who is sponsoring clinical trial NCT05597462?
This trial is sponsored by Journey Medical Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05597462 being conducted?
This trial has 2 study locations across New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05597462's enrollment target sits among peer trials
60 16th of 23 higher than 7 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Agent for Treatment of Red Skin
COMPLETED · Phase 1
-
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
COMPLETED · Phase 1
-
Timolol for the Treatment of Acne and Rosacea
COMPLETED · Phase 1
-
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
COMPLETED · Phase 1
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI